Kringle Pharma,Inc. (4884) Stock Price

Kringel Pharma is a university-derived bioventure engaged in research and development of pharmaceuticals using recombinant human HGF protein. The company aims to advance treatments for intractable diseases through to manufacturing and regulatory approval. It focuses clinical trials on areas with limited patient populations, including acute spinal cord injury, vocal cord scarring, ALS, and acute kidney injury.

Primary customers include advanced medical institutions, university hospitals, pharmaceutical companies, and wholesalers serving as development and commercialization partners. The company plans to reach patients through specialized medical facilities. Revenue streams include upfront contract payments, milestone payments, post-launch royalties, product sales, and active pharmaceutical ingredient supply. Public subsidies and collaborative research funding are also important pillars of development financing.

The business is concentrated in a single segment: pharmaceutical development, with HGF-based drug candidates as the core pipeline. The company holds formulation patents and manufacturing know-how, outsourcing production to contract manufacturers for efficiency. The company is also pursuing revenue opportunities through indication expansion, international expansion, active pharmaceutical ingredient supply to other companies, and licensing partnerships.

Kringle Pharma's core growth strategy centers on recombinant human HGF protein. The company aims to develop and commercialize therapeutics for intractable diseases through in-house manufacturing and regulatory approval. Rather than prioritizing near-term revenue, the company uses development progress as its key management metric. For acute spinal cord injury, the company completed Phase III patient enrollment in April 2023, finished final patient follow-up in October 2023, and obtained preliminary results in February 2024. It has decided to conduct additional clinical trials and issued its 16th warrant in August 2025 to secure funding. The company is pursuing clear milestones toward regulatory approval.

The company's priority investment focuses on a pipeline using recombinant human HGF protein, concentrated in areas with limited patient populations including spinal cord injury, vocal cord scarring, amyotrophic lateral sclerosis (ALS), and acute kidney injury. Its differentiation strategy emphasizes acquiring in-house manufacturing and marketing approval while accumulating formulation design and manufacturing expertise. The company improves efficiency by combining internal capabilities with external contract manufacturing. For vocal cord scarring Phase III, clinical trials began in November 2022, and as of January 2025, patient enrollment is underway at eight facilities. The company also leverages public research support, including AMED's CiCLE program adoption, to reduce development burden.

For new market development and business expansion, the company positions active pharmaceutical ingredient (API) supply and licensing as important revenue streams. Through a business partnership with Claritas Biotherapeutics established in September 2023, Kringle Pharma has begun optimizing API manufacturing methods and has signed an API supply contract with Claritas. The company aims to establish a global supply system in the future. It is preparing for U.S. clinical and manufacturing development through warrant issuance for fundraising (the 13th warrant issued in September 2023, exercised in May 2024). Once funding permits, the company plans to expand its pipeline, such as resuming development for acute kidney injury.

Regarding technological innovation, the company prioritizes deepening trial design and biomarker analysis based on insights from previous clinical trials. Following Phase II ALS results, Kringle Pharma signed a joint research agreement with Tohoku University in April 2024 to identify patient populations most likely to benefit from treatment. On the manufacturing side, the company is implementing process improvements to support large-scale supply. By advancing clinical data collection and manufacturing efficiency in parallel, the company aims to increase the success probability of regulatory submission and market launch.